Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).

Rheumatol Ther · 2019 · PMC6858431 · PMID 31642045

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this post hoc analysis of patients with early RA and poor prognostic factors with an inadequate response to MTX across several outcome measures (except radiographs), abatacept showed a trend towards greater efficacy compared with adalimumab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.